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Abstract
Background: Uveal melanoma (UM) is the most common primary intraocular tumor in adults,
leading to metastasis in 40% of the cases and ultimately to death in 10 years, despite local and/or
systemic treatment. The c-kit protein (CD117) is a membrane-bound tyrosine kinase receptor and
its overexpression has been observed in several neoplasms. Imatinib mesylate is a FDA approved
compound that inhibits tyrosine quinase receptors, as well as c-kit. Imatinib mesylate controls
tumor growth in up to 85% of advanced gastrointestinal stromal tumors, a neoplasia resistant to
conventional therapy.
Methods: Fifty-five specimens of primary UM selected from the archives of the Ocular Pathology
Laboratory, McGill University, Montreal, Canada, were immunostained for c-kit. All cells displaying
distinct immunoreactivity were considered positive. Four human UM cell lines and 1 human uveal
transformed melanocyte cell line were tested for in vitro proliferation Assays (TOX-6) and invasion
assay with imatinib mesylate (concentration of 10 µM).
Results: The c-kit expression was positive in 78.2% of the UM. There was a statistical significant
decrease in the proliferation and invasion rates of all 5 cell lines.
Conclusion:  The majority of UM expressed c-kit, and imatinib mesylate does decrease the
proliferation and invasion rates of human UM cell lines. These results justify the need for a clinical
trial to investigate in vivo the response of UM to imatinib mesylate.
Background
Uveal melanoma (UM) is the most common primary
intra-ocular tumour in adults [1], with an incidence of five
to six individuals per million people [2]. Forty percent of
UM patients will progress from local to systemic disease
developing metastasis that will ultimately lead to death
after 10 years of diagnosis, despite the treatment options
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such as local radiotherapy, enucleation and systemic
chemotherapy [3].
C-kit (Kit, CD117, stem cell factor receptor) is a 145 kDa
transmembrane tyrosine kinase protein that acts as a type-
III receptor. The c-kit proto-oncogene, located on chromo-
some 4q11-21, encodes the c-kit, which ligand is the stem
cell factor (SCF, steel factor, kit ligand, mast cell growth
factor) [4,5]. Tyrosine phosphorylation by protein tyro-
sine kinases is of particular importance in cellular signal-
ling and can mediate signals for major cellular processes,
such as proliferation, differentiation, apoptosis, attach-
ment, and migration. The role of c-kit expression has been
studied in hematologic and solid tumours, such as acute
leukemias [6], and gastrointestinal stromal tumors (GIST)
[7].
The clinical importance of c-kit expression in malignant
tumors relies on the existence of a compound (imatinib
mesylate, STI571, Gleevec®, Novartis Pharma AG Basel,
Switzerland) that specifically inhibits tyrosine kinase
receptors [8]. Moreover, a clinically relevant breakthrough
has been the finding of remarkable anti-tumor effects of
this compound in GIST, a group of tumors regarded as
being generally resistant to conventional chemotherapy
[9]. Imatinib mesylate has been approved by the United
States-FDA to treat c-kit positive GIST and Philadelphia-
chromosome-positive chronic myelogenous leukemia
[10]. The purpose of this article is to study the immunoex-
pression of c-kit in UM, as well as the in vitro effects of
imatinib mesylate on UM cell lines.
Materials and methods
Paraffin blocks
Formalin-fixed, paraffin-embedded blocks from enuclea-
tion of primary choroidal melanoma were collected from
the archives of the Henry C. Witelson Ocular Pathology
Laboratory, McGill University, Montreal, Canada from
the years 1980–2004. All the cases have sufficient tumor
material for analysis. The tumors with irradiation were
excluded.
Immunohistochemistry
Immunohistochemistry was performed using the polyclo-
nal anti-CD117 antibody A4502 (Dako, Mississauga,
Ontario, Canada). The antibody was applied at a dilution
of 1:300 for 18 h at 4°C, after 15 minutes in 10 nmol/l cit-
rate buffer (pH 6.0) for antigen retrieval. Endogenous per-
oxidase was blocked using 0.3% hydrogen peroxidase
diluted in methanol for 30 minutes. A standard avidin-
biotin complex (ABC) technique using diaminobenzidine
was used for visualization, with a red colouring stain to
avoid misinterpretation in pigmented tumors. A case of
KIT-positive Gastrointestinal Stromal Tumor (GIST) was
used as control. Negative control sections were incubated
with normal rabbit serum instead of the primary
antibody.
After tissue processing, all cells displaying distinct immu-
noreactivity were considered positive, irrespective of
staining intensity. We assigned the results of c-kit staining
as negative when no staining was present, low when less
than 50%, and high when more than 50% of melanoma
cells were positive. The immunoreactivity was categorized
as cytoplasmatic or membranous expression using the
grade system described above. In order to better character-
ize the c-kit expression in uveal melanomas, the expres-
sion in the different cell types (spindle and epithelioid –
modified Callender's classification) was analysed, in the
A. Choroidal UM displaying high expression of c-kit Figure 1
A. Choroidal UM displaying high expression of c-kit. The 
above retina is somewhat detached. Figure 1B. UM com-
posed of epithelioid cells showing a cell membrane pattern of 
immunostain.Journal of Carcinogenesis 2005, 4:19 http://www.carcinogenesis.com/content/4/1/19
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mixed cell, predominant epithelioid and predominant
spindle tumors.
Cell Culture
Four human UM cell lines (92.1, SP6.5, MKT-BR, OCM-1)
and one human uveal transformed melanocyte cell line
(UW-1) were incubated at 37°C in a humidified 5% CO2-
enriched atmosphere. The cells were cultured in RPMI-
1640 medium (Invitrogen, Burlington, Ontario, Canada),
supplemented with 5% heat inactivated fetal bovine
serum (FBS), 1% fungizone, and 1% penicillin-strepto-
mycin purchased from Invitrogen (Burlington, Ontario,
Canada). Cells were cultured as a monolayer in 25 cm2
flasks (Fisher, Whitby, Ontario, Canada) and observed
twice weekly, at every media change, for normal growth
by phase contrast microscopy. The cultures were grown to
confluence and passage by treatment with 0.05% trypsin
in EDTA (Fisher) at 37°C and washed in 7 ml RPMI-1640
media before being centrifuged at 120 g for 10 minutes to
form a pellet. Cells were then suspended in 1 ml of
medium and counted using the Trypan Blue dye exclusion
test.
The UM cell lines 92.1, SP6.5, and MKT-BR were estab-
lished by Dr. Jager (University Hospital Leiden, The Neth-
erlands), Dr. Pelletier (Laval University, Quebec,
Canada), Dr. Belkhou (CJF INSERM, France), respectively.
Dr. Albert (University of Wisconsin-Madison, USA) estab-
lished the OCM-1 and UW-1 cell lines [11,12].
In Vitro Invasion Assay
A modified Boyden chamber consisting of a polyethelene
teraphthalate membrane (PET) with 8-um diameter
pores, precoated with Matrigel, an artificial basement
membrane, (Beckton Dickenson Labware, Bedford, MA)
was used as previously described [13], to assay for invasive
ability. PET membrane without Matrigel was used as a
control.
Briefly, 1.25 × 105 cells were added to the upper chamber
in RPMI-1640 medium with 0.1% FBS. RPMI-1640
medium with 10% FBS was added to the lower chamber
as a chemoattractant to obtain the baseline invasive abil-
ity of the cell lines. The effect of imatinib mesylate on
invasion was assayed by adding 10 µM of imatinib
mesylate to the RPMI-1640 medium supplemented with
10% FBS in the upper chamber. The concentrations of
imatinib mesylate was chosen based on the blood levels
reported in previous studies with the maximum tolerated
dose of imatinib mesylate on clinical trials [14]. The
chambers were then incubated at 37°C in a 5% CO2-
enriched atmosphere for 48 hours to allow for cellular
invasion through the Matrigel.
A. Photomicrograph of UM cells without Imatinib mesylate  (control) invading through Matrigel (200×) Figure 2
A. Photomicrograph of UM cells without Imatinib mesylate 
(control) invading through Matrigel (200×). Figure 2B. Phot-
omicrograph of UM cells treated with Imatinib mesylate 
invading through Matrigel (200×).
Table 1: High, low and negative expression of c-kit in different 
cell types and different patterns of stain.
High expression Low expression Negative
Spindle cells 36.8% 57.9% 5.3%
Epithelioid cells 41.5% 53.6% 4.9%
Cell membrane 100% 30.4% ------
Cytoplasmatic 100% 100% ------Journal of Carcinogenesis 2005, 4:19 http://www.carcinogenesis.com/content/4/1/19
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Non-invading cells were removed from the upper cham-
ber by gently wiping the surface of the membrane with a
moist cotton swab. Membranes were removed and then
stained using a Diff-Quick staining set, which stains cell
nuclei purple and cytoplasm pink. Stained cells were
counted microscopically in 20 high-powered fields, ran-
domly. Only cells whose nuclei had completely invaded
through the membrane were counted. Each experimental
condition, including control, was performed in triplicate
and the average number of invading cells was then calcu-
lated for all experimental conditions.
Percent invasion was determined for each cell line under
each experimental condition using the following formula:
% invasion = (mean number of cells invading through the
matrigel/mean number of cells migrating through control
PET membrane) multiplied by a hundred. The cell lines
were then ranked according to their invasive ability.
In Vitro Proliferation Assay
The Sulforhodamine-B based assay kit (TOX-6, Sigma-
Aldrich) was performed as per the National Cancer Insti-
tute protocol [15]. Briefly, five human UM cell lines were
seeded into wells at a concentration of 2.5 × 103 cells per
well, in a minimum of six wells per cell line. A row of 8
wells exposed to only RPMI-1640 medium was used as a
control. Twenty-four hours following seeding, imatinib
mesylate was added to the experimental wells. The con-
centration of imatinib mesylate was 10 µM [14]. Cells
were allowed to incubate for 48 hours following cell seed-
ing. Following this 48 hour period, cells were fixed to the
bottom of the wells using a solution of 50% Trichloroace-
tic acid (TCA) for 1 hour at 4°C. Plates were then rinsed
with distilled water, to remove TCA and medium, and air
dried. The Sulforhodamine-B dye was added to each well
and allowed to stain for 25 minutes. The Sulforhodamine-
B dye was subsequently removed by washing with a 10%
acetic acid solution and once more allowed to air dry. The
dye that was incorporated into the fixed cells at the bot-
tom of the wells was solubilized in a 10 mM solution of
Tris. The absorbance of the solute was measured using a
microplate reader at a wavelength of 510 nm. This gave a
comparison of control cell proliferation rate over 48
hours compared to proliferation rate of cells exposed to
imatinib mesylate during the same time period at a dose
of 10 µM.
Statistical Analysis
The differences in invasion rates under three experimental
conditions for each uveal melanoma cell line were deter-
mined using the ANOVA test. A p value of less than 0.05
was considered statistically significant. Calculations were
computer-based (SPSS 11.5, SPSS Inc., Chicago, Illinois,
USA).
The graph shows the invasion assay results for each cell line  with experimental conditions Figure 3
The graph shows the invasion assay results for each cell line 
with experimental conditions. The blue bar for each repre-
sents the control proliferation without Imatinib Mesylate, and 
the red bar with the compound. A statistical difference was 
seen for the five cell lines after 10 µM exposure.
The graph shows the proliferation assay results comparing a  control and the Imatinib mesylate exposure cells Figure 4
The graph shows the proliferation assay results comparing a 
control and the Imatinib mesylate exposure cells. A statistical 
difference was seen for the five cell lines after 10 µM 
exposure.Journal of Carcinogenesis 2005, 4:19 http://www.carcinogenesis.com/content/4/1/19
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Results
Fifty-five cases of UM were studied. Eight seven percent of
the tumors (n = 48) were classified as mixed cell type
(spindle and epithelioid cells), 9% (n = 5) had predomi-
nance of epithelioid cells, and 3.6% (n = 2) of spindle
cells.
Seventy-eight percent of cases (n = 43) were found to be c-
kit positive (Figure 1A). Among the positive cases, 46.5%
(n = 20) presented with what was considered as high
expression. All lesions with high immunoreactivity (n =
20) had cytoplasmic and cell membrane expression.
Meanwhile, among lesions with low immunoreactivity (n
= 23), 100% presented a cytoplasmatic reaction and just
30.4% (n = 7) presented with a cell membrane stain-pat-
tern (Figure 1B). (Table 1)
The percent invasion of cell lines according to the baseline
invasion without imatinib mesylate was: MKT-BR
(38.4%) > OCM-1 (21.7%) > 92.1 (14.4%) > UW-1
(12%) > SP6.5 (3%). The addition of imatinib mesylate
decreased the invasion in all cell lines: MKT-BR (1.03%);
OCM-1 (0.1%); 92.1 (0.2%); UW-1 (0%); SP6.5 (0%).
The results are shown in Figure 3.
No visible changes in cytomorphology were seen in reac-
tion to the presence of imatinib mesylate (figure 2).
Statistically significant differences between the invasion
rates for the control group and imatinib mesylate group
were found in all cell lines (T test p value < 0.05).
Figure 4 depicts the results from the Sulforhodamine-B
assay. The mean and standard deviation for each cell line
per condition is shown in Table 2. Cells that were directly
exposed imatinib mesylate showed a decrease in prolifer-
ation for all five human cell lines (92.1, MKT-BR, OCM-1,
SP6.5, UW-1) as compared to control (p value of
0.001354991, 0.012655861, 9.47698 × 10-7,
0.002754018 and 5.79576 × 10-6 respectively).
Discussion
It is known that protein tyrosine kinases (PTK) have an
important role in cellular mechanisms, such as differenti-
ation, proliferation and regulatory mechanisms, as well as
in signal transduction. C-kit is one of these PTK, which is
expressed in a wide variety of human malignancies [16]
including chronic and acute myelogenous leukemia [6],
GIST [7], mastocytosis [17], small cell lung carcinoma
[18], chromophobe renal cell carcinoma [19], cutaneous
[20] and UM [16]. As c-kit is expressed in normal
interstitial cells of Cajal, the progenitor cell of GIST [7],
the present article studies the expression of c-kit in uveal
melanomas, as normal choroidal melanocytes do express
this marker [21].
We demonstrated that more than 75% of UM from our
series are positive for c-kit. This finding, per se, supports
the idea of a clinical trial of imatinib mesylate for UM,
especially in metastatic cases. Once metastatic disease is
detected, no effective method of systemic therapy has
been identified [3]. Moreover, not 100% of GIST is posi-
tive for c-kit. In fact, 6% of GIST are c-kit negative [22].
Before the imatinib mesylate "era", metastatic GIST had a
median survival times ranging between 10–20 months
[23]. Nowadays, imatinib mesylate controls tumor
growth in up to 85% of advanced GIST [24], with 90% of
acceptable toxicity [25].
In cutaneous melanoma, c-kit is strongly expressed in
radial growth phase, and weak or no expression is seen in
vertical growth phase and metastatic disease [26].
Therefore, in cutaneous melanomas c-kit expression
appears to be related with stage of the disease. To further
investigate a similar expression of the c-kit in UM, we
observed the cell type (spindle and epithelioid) in which
the c-kit was expressed, as it is well known that spindle cell
type is less aggressive than epithelioid type [1]. None of
the previous studies recorded the cell type in which the
expression was occurring. Mouriaux et al [21] compared
the c-kit expression with cell type tumor (Callendar's clas-
sification) as a correlation to prognostic factor, but did
Table 2: Number of cells counted per control membrane, and percent invasion (mean ± standard deviation) of cells in response to 
experimental conditions.
Cell Line Average Number of Cells in 
Control PET
Percent Invasion of Cells in 
Response to 10% FBS
Percent Invasion of Cells in 
Response to Imatinib 
mesylate
MKT-BR 247 38.43% ± 8.5 1.03% ± 0.2
OCM-1 246.67 21.7% ± 1.9 0.1% ± 0.2
92.1 223 14.4% ± 2.7 0.2% ± 0.2
UW-1 66.33 12% ± 4.8 0% ± 0
SP6.5 266 3% ± 1.5 0% ± 0Journal of Carcinogenesis 2005, 4:19 http://www.carcinogenesis.com/content/4/1/19
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not study which cells were in fact expressing the receptor.
In overall cases, including epithelioid, spindle and mixed
tumors, 90.7% of the epithelioid cells was positive for c-
kit, whereas 83.7% of the spindle cells expressed c-kit.
This finding suggests a different role of c-kit expression in
cutaneous and UMs. Therefore, c-kit can be used to differ-
entiate primary UM from metastatic cutaneous melano-
mas to the uveal tract [27]. As in UM, GIST can be
categorized into spindle cell, epitheloid cell and mixed
cell type, although the prognostic relevance of cell type in
GIST seems to be limited [7]. Like in UM showed by the
present study, the expression of c-kit seems to be equally
distributed among epithelioid and spindle cell morphol-
ogy GISTs [28].
Pache et al [29] and Mouriaux et al [21] found a mem-
brane pattern of immunoreactivity in all their positive
cases (n = 72, 87% of all UM, and n = 43, 75% of all UM,
respectively). The last suggested that cytoplasmatic immu-
noreactivity would be due to a non-mature c-kit rather
than an internalized or truncated form, and the mem-
brane staining could correspond to the c-kit active form.
All-Ericsson  et al [16] considered positive all tumors
expressing c-kit, regardless of the staining location, mean-
ing cell membrane or cytoplasmatic (n = 84, 63% of all
UM). The present study demonstrated that all cases with
high c-kit expression showed both cytoplasmatic and cell-
membrane staining. Regarding the cases with low expres-
sion, 100% had cytoplasmatic expression, but only 30.4%
had cell-membrane pattern of stain. In GISTs, the c-kit
expression is diffuse strong cytoplasmatic and up to 50%
of the cases show cytoplasmatic dot-like (so-called "golgi
pattern") staining [7]. Moreover, there are no studies con-
cerning important differences between cytoplasmatic and
membranous staining in GIST. Therefore, we hypothesize
that all cases expressing c-kit, cytoplasmatic or membra-
nous, should be considered c-kit positive.
GIST is a sarcoma arising from the interstitial cells of
Cajal, harbouring mutation of c-kit. Mutations are
detected in approximately 71% of tumors, the majority
(over 60%) involving exon 11, and less exons 9 and 13
[28]. Choroidal melanoma does not have alterations of
exons 2, 8, 9, 11, 13 and 17 [29]. However, imatinib
mesylate selectively inhibits not only c-kit, but also other
tyrosine kinases such as Bcr-Abl and platelet-derived
growth factor (PDGF) receptor [30]. We could
demonstrate that the decrease of proliferation of UM cells
with imatinib mesylate was very significant, in the 4 UM
cell lines tested and in the human uveal transformed
melanocyte cell line, compared to the control group.
Other studies also support that imatinib mesylate can
decrease UM cells proliferation rates [8]. The mechanism
that c-kit would interfere in UM proliferation could be
other than c-kit mutation, but further studies are neces-
sary to investigate this hypothesis.
The concentration of imatinib mesylate used for the in
vitro studies was 10 µM. This concentration is equivalent
to the highest drug concentration achieved in the blood of
patients receiving 1000 mg/day of imatinib mesylate, the
maximum tolerated dose reported by clinical trials [14].
At that dose, the blood concentration of imatinib
mesylate ranged from 6 to 10 µM [14]. According to clin-
ical trials, the current treatment for GIST is 800 mg/day of
imatinib mesylate [25]. All-Ericsson et al [16] demon-
strated that concentrations of 10 µM of imatinib mesylate
could inhibit the proliferation of 5 UM cell lines in 50%
(2 of them, OCM-1 and 92.1, were also studied in this
article). The different concentrations of imatinib mesylate
tested had different responses according to the cell line.
Pache et al [29] also had the same conclusion. Moreover,
the last demonstrated that imatinib mesylate does not
influence the proliferation of normal uveal melanocytes.
The human uveal transformed melanocyte cell line UW-1
studied in the present article demonstrated a significant
decrease in proliferation and invasion rates when treated
with imatinib mesylate. UW-1 was originally derived from
uveal melanocytes, and transformed into malignant
melanoma cells throughout culture. We hypothesize that
imatinib mesylate could act in a more general pathway
than c-kit receptor, as it does inhibit UW-1 proliferation
and invasion rates.
The effect on invasion of UM cells in response to imatinib
mesylate has never been published before. Tumor cells
must possess invasive abilities in order for metastasis to
occur. Due to the lack of lymphatics in the eye, uveal
melanoma cells must leave the primary tumor via hema-
togenous dissemination, with metastasis almost exclu-
sively occurring in the liver [2]. Our study demonstrated
that imatinib mesylate markedly reduced the invasiveness
of all cell lines tested. The invasion assay is important to
show the ability of cells to invade a basement membrane,
simulating the escape of cells from the primary tumor, as
well as the implantation of cells at the site of the metasta-
sis. The use of artificial basement membrane can study the
invasive response of cells to drugs by counting the amount
of cells that invade the matrigel layer. A drug that can
inhibit or reduce the invasiveness ability of the UM cells
could be beneficial, as most of the UM are nowadays
treated conservatively [31]. Decreasing the invasiveness of
the tumoral cells, the drug would also decrease the ability
of implantation of cells at the site of metastasis. Therefore,
imatinib mesylate would be beneficial not only for UM
patients that already developed metastasis, but also for
patients without any sign of metastatic disease.Publish with BioMed Central    and   every 
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Conclusion
We could demonstrate that primary choroidal melano-
mas express c-kit and imatinib mesylate decrease the pro-
liferation rate and invasiveness of uveal melanoma cells in
vitro. Therefore, our data supports a clinical trial for stud-
ying imatinib mesylate in uveal melanoma.
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